Lexicon Genetics to Present New Target for Alzheimer's and Other Cognitive Disorders at Research Conference
Tuesday June 24, 7:31 am ET
THE WOODLANDS, Texas, June 24 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced that Thomas H. Lanthorn, Ph.D., director of neurology at Lexicon, will be presenting a new target for learning and memory that could have applications in Alzheimer's and other cognitive disorders. Dr. Lanthorn will speak at the Strategic Research Institute's Psychiatric Drug Discovery & Development Conference in Princeton, New Jersey at 11:40 a.m. EDT on Tuesday, June 24, 2003. This presentation will not be webcast.
Lexicon scientists discovered that inhibiting the LG617 protein in knockout mice resulted in a statistically significant increase in performance in a test of learning and memory, even as they age. Lexicon's LG617 gene encodes a membrane protein that is expressed only in the brain. Lexicon scientists are currently working to develop small molecule drugs against the human target that could have the potential to increase learning, attention and/or memory in patients with various disorders associated with cognitive impairment. This target was first identified from Lexicon's proprietary OmniBank® library.
Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover in living mammals, or in vivo, the physiological functions and pharmaceutical utility of genes. The Company's gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and turn its discoveries into drugs. Additional information about the Company is available through Lexicon's corporate website, www.lexicon-genetics.com . |
